Pelthos Therapeutics Appoints John M. Gay As CFO
Benzinga Newsdesk 7 months ago
NewsManagement
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced John M. Gay has been appointed Chief
Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced John M. Gay has been appointed Chief Financial Officer effective April 10, 2026. Mr. Gay succeeds Francis Knuettel II, who served as Pelthos' Chief Financial Officer since July 2025.
